• Tue news: Merck's Keytruda stages comeback in head and neck cancer. GSK, Pfizer RSV vaccine sales fall. Astellas gene therapy bet. Extreme weather —>drug shortages. J&J discontinues bladder cancer drug. See more on our front page

Mahaffy Securities Fraud

anonymous

Guest
Some people never learn. Last time it was lying about data to inflate the share price, this time it is illegal actions with funds that have held short positions against CLVS for years while assisting Pat's own pockets with low priced equity issuance.